SCHEMBL2675693

SCHEMBL2675693

Nc1ccc2c(c1)CCCCN2C1CCN(C(=O)O)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.43
ATAD2 Q6PL18 1/20 0.43
AGTR2 P50052 6/20 0.41
GFER P55789 2/20 0.41
NOS3 P29474 4/20 0.41
NOS1 P29475 4/20 0.41
PDK1 Q15118 1/20 0.39
PDK2 Q15119 1/20 0.39
PDK3 Q15120 1/20 0.39
PDK4 Q16654 1/20 0.39
AVPR2 P30518 1/20 0.39
NOS2 P35228 1/20 0.38
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
MAPT P10636 1/20 0.36
THRB P10828 1/20 0.36
ALOX15 P16050 1/20 0.36
YWHAG P61981 1/20 0.36
KMT2A Q03164 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2675527 0.96 BRD4 (0.46) BRD4ATAD2AGTR2GFERNOS3
SCHEMBL2675588 0.91 ATAD2 (0.40) BRD4ATAD2GFERNOS3NOS1
SCHEMBL27778267 0.89 BRD4 (0.48) BRD4ATAD2AGTR2GFERNOS3
SCHEMBL2675497 0.86 HDAC1 (0.42) AGTR2NOS3NOS1PDK1PDK2
SCHEMBL4107840 0.84 NR1H2 (0.51)
SCHEMBL2675482 0.83 AGTR2 (0.54) AGTR2AVPR2KDM4EMEN1MAPT
SCHEMBL2675368 0.82 DPP4 (0.42) AGTR2NOS3NOS1PDK1PDK2
SCHEMBL2675691 0.80 NR1H2 (0.52) BRD4ATAD2
SCHEMBL2675885 0.80 NOS1 (0.55) BRD4ATAD2GFERNOS3NOS1
SCHEMBL2675143 0.79 NR1H2 (0.53)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173813-B2 selectively inhibit neuronal nitric oxide synthase in combination with other pharmaceutically active agents; antidepressants NEURAXON, INC. (CA) 2012-05-08 US disclosed
EP-2139886-A1 QUINOLONE AND TETRAHYDROQUINOLINE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY Neuraxon Inc. (CA) 2010-01-06 EP disclosed
WO-2008116308-A1 QUINOLONE AND TETRAHYDROQUINOLINE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY NEURAXON, INC. (CA) 2008-10-02 WO disclosed
US-20080234237-A1 QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY NEURAXON, INC. (CA) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234237-A1 QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY NOS1, NOS2, NOS3 BRD4 986/4885ATAD2 1833/4885AGTR2 1371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.